Sixteen trials evaluated EGFR-tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant NSCLC, and the remaining two trials assessed the use of crizotinib, an ALK-TKI, to treat ALK-rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.